[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Gu et al., 2013 - Google Patents

Recent advances in design and fabrication of upconversion nanoparticles and their safe theranostic applications

Gu et al., 2013

Document ID
4790041719832348499
Author
Gu Z
Yan L
Tian G
Li S
Chai Z
Zhao Y
Publication year
Publication venue
Advanced Materials

External Links

Snippet

Lanthanide (Ln) doped upconversion nanoparticles (UCNPs) have attracted enormous attention in the recent years due to their unique upconversion luminescent properties that enable the conversion of low‐energy photons (near infrared photons) into high‐energy …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules

Similar Documents

Publication Publication Date Title
Gu et al. Recent advances in design and fabrication of upconversion nanoparticles and their safe theranostic applications
Dong et al. Lanthanide nanoparticles: from design toward bioimaging and therapy
Generalova et al. Multicomponent nanocrystals with anti-Stokes luminescence as contrast agents for modern imaging techniques
Wang et al. Upconversion nanoparticles for photodynamic therapy and other cancer therapeutics
Jia et al. Recent advances and prospects of carbon dots in cancer nanotheranostics
Chen et al. Current advances in lanthanide‐doped upconversion nanostructures for detection and bioapplication
Rafique et al. Recent advances of upconversion nanoparticles in theranostics and bioimaging applications
Cai et al. Optical nano-agents in the second near-infrared window for biomedical applications
Xu et al. Recent advances in near-infrared emitting lanthanide-doped nanoconstructs: Mechanism, design and application for bioimaging
Su et al. A supramolecular strategy to engineering a non-photobleaching and near-infrared absorbing nano-J-aggregate for efficient photothermal therapy
Park et al. Theranostic probe based on lanthanide‐doped nanoparticles for simultaneous in vivo dual‐modal imaging and photodynamic therapy
Mahata et al. Near-infrared-triggered upconverting nanoparticles for biomedicine applications
Zhou et al. Upconversion nanophosphors for small-animal imaging
Gulzar et al. Upconversion processes: versatile biological applications and biosafety
Zhang et al. Engineering lanthanide-based materials for nanomedicine
Qian et al. Light-activated hypoxia-responsive nanocarriers for enhanced anticancer therapy
Wang et al. Near-infrared light induced in vivo photodynamic therapy of cancer based on upconversion nanoparticles
Cheng et al. Upconversion nanoparticles and their composite nanostructures for biomedical imaging and cancer therapy
Xu et al. An intelligent nanoplatform for imaging-guided photodynamic/photothermal/chemo-therapy based on upconversion nanoparticles and CuS integrated black phosphorus
Cui et al. Gold nanoclusters–indocyanine green nanoprobes for synchronous cancer imaging, treatment, and real-time monitoring based on fluorescence resonance energy transfer
Lei et al. Emerging biomaterials: Taking full advantage of the intrinsic properties of rare earth elements
Zhao et al. Facile preparation of double rare earth-doped carbon dots for MRI/CT/FI multimodal imaging
Wei et al. ZnO: Er, Yb, Gd particles designed for magnetic-fluorescent imaging and near-infrared light triggered photodynamic therapy
Wang et al. Upconversion nanocomposites for photo-based cancer theranostics
Naher et al. Upconversion nanoparticles (UCNPs): Synthesis methods, imaging and cancer therapy